Melissa Brand Image

Melissa Brand

Intellectual Property Counsel

Radius Health, Inc.

Melissa Brand is Intellectual Property Counsel at Radius Health. In this role, Ms. Brand leads global patent portfolio development, counsels on freedom to operate and enforcement issues, and provides strategic support for transactional matters.

Prior to her role at Radius, Ms. Brand served as the Assistant General Counsel for Intellectual Property at the Biotechnology Innovation Organization and worked in private practice at Latham & Watkins and Wilson Sonsini Goodrich & Rosati. Ms. Brand also served as a law clerk to the Honorable Kimberly A. Moore at the United States Court of Appeals for the Federal Circuit. She also teaches a course on Intellectual Property & Medicines as an adjunct professor at the Georgetown University Law Center.

Recent Articles by Melissa Brand

TRIPS IP Waiver Could Establish Dangerous Precedent for Climate Change and Other Biotech Sectors

While the discussions around waiving intellectual property (IP) rights set forth in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) are currently (and somewhat amorphously) limited to COVID-19 related drug and medical products, it is probably shortsighted to ignore the implications for other technologies critical to sustaining our environment and advancing a more healthful world. In fact, if we want to ensure continued investment in these technologies, we should be very concerned about the message conveyed by the international political tide: if you overcome a challenging scientific problem and your solution has the potential to save lives, be prepared to be subjected to intense political pressure and to potentially hand over your technology without compensation and regardless of the consequences.

BIO Urges NIST to Continue Successful Public-Private Partnership in Recent Comments

The Biotechnology Innovation Organization (BIO) recently submitted comments in support of a National Institute of Standards and Technology [NIST] rulemaking on “Rights to Federally Funded Inventions and Licensing of Government Owned Inventions.” The proposed rule caps a nearly three-year effort by NIST, through engagement with stakeholders, to improve federal technology transfer and the commercialization of federally funded inventions. That effort resulted in a comprehensive Green Paper, “Unleashing American Innovation” in April 2019, which reviewed federal research efforts and made detailed recommendations to maximize the taxpayers’ return on investment.

Past Events with Melissa Brand